Lamisil cream

البلد: أرمينيا

اللغة: الإنجليزية

المصدر: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

العنصر النشط:

terbinafine (terbinafine hydrochloride)

متاح من:

GlaxoSmithKline Consumer Healthcare S.A.

ATC رمز:

D01AE15

INN (الاسم الدولي):

terbinafine (terbinafine hydrochloride)

جرعة:

10mg/g

الشكل الصيدلاني:

cream

الوحدات في الحزمة:

15g aluminium tube, 15g laminated tube

نوع الوصفة الطبية :

OTC

الوضع إذن:

Registered

تاريخ الترخيص:

2020-01-09

خصائص المنتج

Global Drug Regulatory Affairs
LAMISIL1% CREAM
Terbinafine
SUMMARY OF PRODUCT CHARACTERISTICS
Property of GSK Consumer Healthcare S.A.
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK Consumer Healthcare S.A.
CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
...............................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
..................................................... 3
3.
PHARMACEUTICAL FORM
....................................................................................................
3
4.
CLINICAL PARTICULARS
......................................................................................................
3
4.1.
Therapeutic indications
..................................................................................................
3
4.2.
Posology and method of administration
.........................................................................
3
4.3.
Contra-indications
..........................................................................................................
4
4.4.
Special warnings and precautions for use
......................................................................
4
4.5.
Interactions with other medicinal products and other forms of
interaction ................... 4
4.6.
Pregnancy and lactation
.................................................................................................
4
4.7.
Effects on ability to drive and use machines
................................................................. 5
4.8.
Undesirable effects
.........................................................................................................
5
4.9.
Overdose
........................................................................................................................
5
5.
PHARMACOLOGICAL PROPERTIES
....................................................................................
6
5.1.
Pharmacodynamic properties
.........................................